Diabetic neurogenic bladder (DNB) is a collective term for a series of lower urinary tract symptoms and complications caused by dysfunction of the bladder and urethra in patients with diabetes mellitus (DM), due to autonomic neuropathy, especially parasympathetic nerve dysfunction. It is characterized by a high incidence, insidious onset, and complex pathogenesis. There are numerous clinical treatment methods, but most of them have unsatisfactory efficacy, more adverse reactions, and high treatment costs, which severely impact the patients' quality of life. This article summarizes the pathogenesis, drug treatment, non- surgical treatment, and surgical treatment, and proposes the shortcomings of current treatments and future research directions, aiming to provide a reference for the clinical diagnosis and treatment of DNB.

1.Han X, Gao Y, Wang S, et al. Effect of electroacupuncture on diabetic neurogenic bladder: a randomized controlled trial protocol[J]. Medicine (Baltimore), 2020, 99(17): e19843. DOI: 10.1097/MD.0000000000019843.

2.Tang F, Cheng Z, Wen X, et al. Effect of continuous care intervention on the quality of life in patients with neurogenic bladder dysfunction[J]. J Int Med Res, 2019, 47(5): 2011-2017. DOI: 10.1177/0300060519833563.

3.韩栩珂, 陈一丁, 陈慧臻, 等. 2型糖尿病神经源性膀胱大鼠模型的建立与评价[J]. 中国组织工程研究, 2022, 26(17): 2713-2719. [Han XK, Chen YD, Chen HZ, et al. Establishment and evaluation of neurogenic bladder model in rats with type 2 diabetes mellitus[J]. Chinese Journal of Tissue Engineering Research, 2022, 26(17): 2713-2719.] http://qikan.cqvip.com/Qikan/Article/Detail?id=7106214898.

4.Panigrahy R, Singh B, Das SK. Diabetic uropathy and bladder dysfunctions[J]. Diabetes Metab Syndr. 2017, 11(1): 81-82. DOI: 10.1016/j.dsx.2016.06.018.

5.Ma C, Cheng YJ, Xiao N. Research progress of mesenchymal stem cell in the treatment of diabetic bladder dysfunction[J]. Zhonghua Wai Ke Za Zhi, 2022, 60(11): 1035-1040. DOI: 10.3760/cma.j.cn112139-20220530-00245.

6.Inouye BM, Hughes FM Jr, Jin H, et al. Diabetic bladder dysfunction is associated with bladder inflammation triggered through hyperglycemia, not polyuria[J]. Res Rep Urol, 2018, 10: 219-225. DOI: 10.2147/RRU.S177633.

7.Donnan J, Ledger S. An update on the treatment and management of diabetic peripheral neuropathy[J]. CANNT J, 2006, 16(4): 32-38. https://pubmed.ncbi.nlm.nih.gov/17252899/.

8.曹迎东, 李翠凡, 夏武宪, 等. 糖尿病神经性膀胱患者血浆同型半胱氨酸、血清叶酸、维生素B12的水平及尿动力学变化分析[J]. 中国糖尿病杂志, 2018, 26(7): 563-565. [Cao YD, Li CF, Xia WX, et al. Analysis of the circulating levels of Hcy, FA and VitB12 and urinary dynamics in patients with DNB[J]. Chinese Journal of Diabetes, 2018, 26(7): 563-565.] DOI: 10.3969/j.issn. 1006-6187.2018.07.006.

9.李宏亮, 余叶蓉. 2型糖尿病患者血管内皮细胞功能异常及其机理研究[J]. 中华糖尿病杂志, 2004, 12(2): 146-148. [Li HL, Yu YR. Abnormal function of vascular endothelial cells in patients with type 2 diabetes mellitus and its mechanism[J]. Chinese Journal of Diabetes, 2004, 12(2): 146-148.] DOI: 10.3321/j.issn.1006-6187. 2004.02.021.

10.Liao LM, Maderbacher H. Neurourology. Theory and practice[M]. Berlin：Springer Netherlands, 2019.

11.黄健，张旭.中国泌尿外科和男科疾病诊断治疗指南[M].北京:科学出版社, 2022. [Huang J, Zhang X. Guidelines for the diagnosis and treatment of urological and andrological diseases in China[M]. Beijing: Science Press, 2022.]

12.Takeda M, Homma Y, Araki I, et al. Predictive factors for the effect of the α1-D/A adrenoceptor antagonist naftopidil on subjective and objective criteria in patients with neurogenic lower urinary tract dysfunction[J]. BJU Int, 2011, 108(1): 100-107. DOI: 10.1111/j.1464-410X. 2010.09682.x.

13.Dasgupta R. Prostaglandin E2 and bethanechol in combination for treating detrusor underactivity[J]. BJU Int, 2004,94(1):191-192. DOI: 10.1111/j.1464-410X.2004.4949b.x.

14.Takeda M, Homma Y, Araki I, et al. Predictive factors for the effect of the α1-D/A adrenoceptor antagonist naftopidil on subjective and objective criteria in patients with neurogenic lower urinary tract dysfunction[J]. BJU Int, 2011,108(1):100-107. DOI: 10.1111/j.1464-410X.2010.09682.x.

15.张何英. α-硫辛酸、莫沙必利、甲钴胺联合治疗糖尿病神经源性膀胱中的临床疗效观察[J]. 临床医药文献电子杂志, 2020, 7(23): 148. [Zhang HY. Observation of the clinical efficacy of the combination of α-lipoic acid, mosapride and methylcobalamin in the treatment of diabetic neurogenic bladder[J]. Electronic Journal of Clinical Medical Literature, 2020, 7(23): 148.] DOI: 10.16281/j.cnki.jocml.2020.23.143.

16.何彩红, 朱水染. α-硫辛酸联合依帕司他与硫辛酸单用对糖尿病神经源性膀胱的疗效观察[J]. 中国医药科学, 2019, 9(14): 30-33. [He CH, Zhu SR. Therapeutic effect of α-lipoic acid combined with epalrestat and α-lipoic acid in the treatment of diabetic neurogenic bladder[J]. China Medicine and Pharmacy, 2019, 9(14): 30-33.] DOI: 10.3969/j.issn.2095-0616.2019.14.010.

17.Wein AJ. Re: efficacy and safety of combination pharmacotherapy for patients with overactive bladder: a rapid evidence assessment[J]. J Urol, 2020, 204(6): 1388-1389. DOI: 10.1097/JU.0000000000001286.03.

18.叶发根, 廖解志, 周晓慧, 等. 盐酸特拉唑嗪联合甲钴胺对糖尿病神经源性膀胱患者疗效及其机制的研究[J]. 中华全科医学, 2017, 15(8): 1365-1367. [Ye FG, Liao JZ, Zhou XH, et al. Effect and mechanism of terazosin hydrochloride combined Mecobalamin on diabetic neurogenic bladder[J]. Chinese Journal of General Practice, 2017, 15(8): 1365-1367.] DOI: 10.16766/j.cnki.issn.1674-4152.2017.08.027.

19.Aslan AR, Kogan BA. Conservative management in neurogenic bladder dysfunction[J]. Curr Opin Urol, 2002, 12(6): 473-477. DOI: 10.1097/00042307-200211000-00005.

20.Reitz A, Haferkamp A, Wagener N, et al. Neurogenic bladder dysfunction in patients with neoplastic spinal cord compression: adaptation of the bladder management strategy to the underlying disease[J]. NeuroRehabilitation, 2006, 21(1): 65-69. https://pubmed.ncbi.nlm.nih.gov/16720939/.

21.Ginsberg DA, Boone TB, Cameron AP, et al. The AUA/SUFU guideline on adult neurogenic lower urinary tract dysfunction: treatment and follow-up[J]. J Urol, 2021, 206(5): 1106-1113. DOI: 10.1097/JU.0000000000002239.

22.Liu J, Luo C, Xiao W, et al. Urinary tract infections and intermittent catheterization among patients with spinal cord injury in Chinese community[J]. Sci Rep, 2023, 13(1): 17683. DOI: 10.1038/s41598-023-44697-0.

23.Li X, Li X, Zhou Z, et al. Feasibility of a transcutaneous tibial nerve stimulation device use in overactive bladder patients: a pilot study from a single tertiary care center[J]. Front Neurol, 2022, 13: 872200. DOI: 10.3389/fneur. 2022.872200.

24.Chen G, Larson JA, Ogagan PD, et al. Post-stimulation inhibitory effect on reflex bladder activity induced by activation of somatic afferent nerves in the foot[J]. J Urol, 2012, 187(1): 338-343. DOI: 10.1016/j.juro.2011.09.012.

25.Chen G, Liao L, Wang Z, et al. Increasing bladder capacity by foot stimulation in rats with spinal cord injuries[J]. BMC Urol, 2017, 17(1): 85. DOI: 10.1186/s12894-017-0277-4.

26.Deng H, Liao L, Wu J, et al. Clinical efficacy of intravesical electrical stimulation on detrusor underactivity: 8 years of experience from a single center[J]. Medicine (Baltimore), 2017, 96(38): e8020. DOI: 10.1097/MD. 0000000000008020.

27.Joussain C, Denys P. Electrical management of neurogenic lower urinary tract disorders[J]. Ann Phys Rehabil Med, 2015, 58(4): 245-250. DOI: 10.1016/j.rehab.2015.07.005.

28.马淑义, 甄玉婷. 用超短波治疗糖尿病神经原性膀胱的效果研究[J]. 当代医药论丛, 2017, 15(7): 40-41. [Ma SY, Zhen YT. Study of the effect of ultrashort wave in the treatment of diabetic neurogenic bladder[J]. Contemporary Medicine Forum, 2017, 15(7): 40-41.] DOI: 10.3969/j.issn. 2095-7629.2017.07.028.

29.Juszczak K, Adamczyk P, Maciukiewicz P, et al. Clinical outcomes of intravesical injections of botulinum toxin type A in patients with refractory idiopathic overactive bladder[J]. Pharmacol Rep, 2018, 70(6): 1133-1138. DOI: 10.1016/j.pharep.2018.08.002.

30.Nambiar A, Lucas M. Chapter 4: guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO)[J]. Neurourol Urodyn, 2014, 33(S3): S21-S25. DOI: 10.1002/nau.22631.

31.杨亚飞, 杨进, 陈林, 等. 骨髓间充质干细胞移植治疗糖尿病神经源性膀胱的研究与进展[J]. 中国组织工程研究, 2017, 21(5): 802-808. [Yang YF, Yang J, Chen L, et al. Bone marrow mesenchymal stem cells transplantation in the treatment of diabetic cystopathy[J]. Chinese Journal of Tissue Engineering Research, 2017, 21(5): 802-808.] DOI: 10.3969/j.issn.2095-4344.2017.05.024.

32.Zaer H, Rasmussen MM, Zepke F, et al. Effect of spinal anterior root stimulation and sacral deafferentation on bladder and sexual dysfunction in spinal cord injury[J]. Acta Neurochir (Wien), 2018, 160(7): 1377-1384. DOI: 10.1007/s00701-018-3557-1.

33.Tilborghs S, De Wachter S. Sacral neuromodulation for the treatment of overactive bladder: systematic review and future prospects[J]. Expert Rev Med Devices, 2022, 19(2): 161-187. DOI: 10.1080/17434440.2022.2032655.